Jiongbo Liao
Publication Activity (10 Years)
Years Active: 2022-2022
Publications (10 Years): 5
Publications (10 Years): 5
Top Venues
Publications
- Zhiying Xu, Bingyi Yang, Jun Guan, Wei-Wei Shan, Jiongbo Liao, Wenyu Shao, Xiao-Jun ChenComparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). Journal of gynecologic oncology 34 (1) (2022)
- Zhiying Xu, Bingyi Yang, Jun Guan, Wei-Wei Shan, Jiongbo Liao, Wenyu Shao, Xiao-Jun ChenComparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). Journal of gynecologic oncology 34 (1) (2022)
- Zhiying Xu, Bingyi Yang, Jun Guan, Wei-Wei Shan, Jiongbo Liao, Wenyu Shao, Xiao-Jun ChenComparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). Journal of gynecologic oncology (2022)
- Zhiying Xu, Bingyi Yang, Jun Guan, Wei-Wei Shan, Jiongbo Liao, Wenyu Shao, Xiao-Jun ChenComparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). Journal of gynecologic oncology 34 (1) (2022)
- Zhiying Xu, Bingyi Yang, Jun Guan, Wei-Wei Shan, Jiongbo Liao, Wenyu Shao, Xiao-Jun ChenComparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). Journal of gynecologic oncology 34 (1) (2022)